PK of New Oral Formulations of Ambroxol Hydrochloride (Lasolvan)

Phase 1, randomised, open-label trial of Ambroxol hydrochloride oral solution (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to 24 h at Steady State and Maximum Measured Concentration of the Analyte in Plasma at Steady State. Started Mar 2014; status: completed.